TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1640806

Group type: EXPERIMENTAL
Intervention: Ethanol (0.85 g/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cocaine HCl (1.25 and 1.9 mg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ethanol (0.85 g/kg) with Cocaine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ethanol with Cocaine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cocaethylene
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (lidocaine and mannitol)
Number of subjects: 11
Study: 6151505

Group type: EXPERIMENTAL
Intervention: Propranolol (maximum 170 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metoprolol (maximum 187.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol (various doses: 10 mg, 17.5 mg, 45 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metoprolol (various doses: 37.5 mg, 187.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inhaled isoprenaline
Number of subjects: 16
Study: 30902396

Group type: EXPERIMENTAL
Intervention: TXA (2 bolus of 10mg/kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 30211993

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating electric toothbrush, stannous fluoride dentifrice, and dental floss
Number of subjects: 120

Group type: COMPARATOR
Intervention: Regular manual toothbrush and anti-cavity sodium fluoride dentifrice
Number of subjects: 120
Study: 26847307

Group type: EXPERIMENTAL
Intervention: CC depth of 6-7 cm (G 6-7)
Number of subjects: 62

Group type: COMPARATOR
Intervention: CC depth of 5-6 cm (G 5-6)
Number of subjects: 62
Study: 25533560

Group type: EXPERIMENTAL
Intervention: Simple conjunctival resection
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Conjunctival resection and scleral fixation
Number of subjects: 33
Study: 22040259

Group type: EXPERIMENTAL
Intervention: Funhaler
Number of subjects: 132

Group type: COMPARATOR
Intervention: Aerochamber Plus
Number of subjects: 132
Study: 20084363

Group type: COMPARATOR
Intervention: Routine follow-up
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Routine follow-up and quarterly telephone contact
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Routine follow-up and monthly telephone contact
Number of subjects: 164
Study: 18773604

Group type: EXPERIMENTAL
Intervention: Intervention group (n=1019)
Number of subjects: 2024

Group type: COMPARATOR
Intervention: Usual Care group (n=1005)
Number of subjects: 2024
Study: 15911037

Group type: EXPERIMENTAL
Intervention: Integrative treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Psychopharmacological therapy
Number of subjects: 30
Study: 12790358

Group type: EXPERIMENTAL
Intervention: In vitro incubation of Tc-99m-HMPAO
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous injection of Tc-99m-HMPAO
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhalation of Tc-99m-HMPAO
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tc-99m-HMPAO adherence to mucus after inhalation
Number of subjects: 19
Study: 10559508

Group type: EXPERIMENTAL
Intervention: HMG CoA reductase inhibitor medication (statins)
Number of subjects: 45
Study: 8907672

Group type: EXPERIMENTAL
Intervention: Luminol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lucigenin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Phorbol 12-myristate 13-acetate
Number of subjects: 47

Group type: COMPARATOR
Intervention: Centrifugation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Swim-up preparation
Number of subjects: 47
Study: 1781468

Group type: EXPERIMENTAL
Intervention: Illumination level of 146 foot-candles
Number of subjects: 10888

Group type: COMPARATOR
Intervention: Illumination level of 45 foot-candles
Number of subjects: 10888

Group type: EXPERIMENTAL
Intervention: Overall prescription error rate
Number of subjects: 10888
Study: 30284352

Group type: COMPARATOR
Intervention: MCT with RT
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: HIIT with RT
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 27629570

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 20
Study: 25953020

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided regional anesthesia (US-RA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 60
Study: 24103080

Group type: EXPERIMENTAL
Intervention: Hormonal indices of adrenarche and gonadarche measured through saliva samples
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Student, parent, and teacher questionnaires; anthropometric measurements
Number of subjects: 1239
Study: 21102589

Group type: EXPERIMENTAL
Intervention: Figitumumab (F) at doses of 10 or 20 mg/kg (PCF10, PCF20)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (PC)
Number of subjects: 110
Study: 20379151

Group type: EXPERIMENTAL
Intervention: Taranabant 0.5 mg
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Taranabant 1 mg
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Taranabant 2 mg
Number of subjects: 784

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 784
Study: 17169593

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group of children with ADHD
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group of children with dyslexia
Number of subjects: 24
Study: 14977698

Group type: EXPERIMENTAL
Intervention: Low α1 antitrypsin (α1-AT) levels
Number of subjects: 5629

Group type: EXPERIMENTAL
Intervention: Heterozygosity of the α1 antitrypsin (α1-AT) Pi genotypes MS or MZ
Number of subjects: 5629
Study: 12599994

Group type: EXPERIMENTAL
Intervention: Diet containing 60 g/day soy protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet containing 30 g/day soy protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet containing 45 g/day soy protein
Number of subjects: 0
Study: 9835668

Group type: EXPERIMENTAL
Intervention: Pressure bandage
Number of subjects: 1075

Group type: COMPARATOR
Intervention: No bandage
Number of subjects: 1075
Study: 8563662

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CB)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal therapy (PI)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Eight sessions of therapy
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sixteen sessions of therapy
Number of subjects: 117
Study: 2682710

Group type: EXPERIMENTAL
Intervention: Hydiphen
Number of subjects: 45

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 45
Study: 8188

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Practolol
Number of subjects: 12
Study: 31432657

Group type: EXPERIMENTAL
Intervention: Patients with periprosthetic infection (n=50)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Patients without infectious complications (n=100)
Number of subjects: 150
Study: 30926189

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (0.75 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intranasal placebo (saline solution)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 120
Study: 28472247

Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 158
Study: 26147544

Group type: EXPERIMENTAL
Intervention: Integrated workplace safety and smoking cessation program
Number of subjects: 328

Group type: COMPARATOR
Intervention: Commercial databases for recruitment
Number of subjects: 328
Study: 23974036

Group type: EXPERIMENTAL
Intervention: TAU plus a twelve-month SUMMIT program participation with personal support
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: TAU plus a twelve-month SUMMIT program participation without personal support
Number of subjects: 236

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 236
Study: 21252259

Group type: EXPERIMENTAL
Intervention: High quartile of soluble CD14 (sCD14) levels
Number of subjects: 275

Group type: COMPARATOR
Intervention: Intestinal fatty acid binding protein (I‐FABP), lipopolysaccharide (LPS), soluble CD14 (sCD14)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Endotoxin core antibody (EndoCAb)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: sCD14
Number of subjects: 275
Study: 19503012

Group type: EXPERIMENTAL
Intervention: Prednisolone 60 mg daily for 5 days, then tapering for 5 days plus placebo
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Valacyclovir 1,000 mg 3 times daily for 7 days plus placebo
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Prednisolone plus valacyclovir
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Presence of pain at Days 11 to 17
Number of subjects: 829
Study: 16877985

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (ATCC 53103)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 12544447

Group type: EXPERIMENTAL
Intervention: High-salt diet (400 mmol/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-salt diet (10 mmol/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mental stress response
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low salt (7.8 +/- 0.9 to 11.2 +/- 1.4 ml/min per 100 ml)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High salt (8.5 +/- 1.2 to 10.4 +/- 1.3 ml/min per 100 ml)
Number of subjects: 25
Study: 10871469

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9062479

Group type: EXPERIMENTAL
Intervention: Low dose T3 treatment for 63 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: High fat diet
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: T3 treatment
Number of subjects: 7
Study: 8269186

Group type: EXPERIMENTAL
Intervention: Angiographic definitions of restenosis
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Early recurrent symptoms
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: History of recurrent angina or positive exercise testing
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Positive exercise testing in patients with angina
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Loss of 2 standard deviations definition
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Loss of 50% absolute gain definition
Number of subjects: 125
Study: 3534021

Group type: EXPERIMENTAL
Intervention: Topical tretinoin (retinoic acid and Retin-A) delivered by cervical cap and inert collagen sponge system
Number of subjects: 0
Study: 29959297

Group type: EXPERIMENTAL
Intervention: Filtek P60
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: X-tra fil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Admira Fusion x-tra
Number of subjects: 30
Study: 26725102

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Drug-eluting balloons (DEB)
Number of subjects: 498
Study: 24584048

Group type: EXPERIMENTAL
Intervention: ISO half‐squats (3 sets of 3‐second maximal isometric)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ECC half‐squats (9.3 +/‐ 1.5 repetitions against 70% of 1RM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CON half‐squats (7.5 +/‐ 1.2 repetitions against 90% of 1RM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: CTRL (rest for 10 minutes)
Number of subjects: 14
Study: 22425057

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion with duodenal switch (BPD/DS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 47
Study: 20585000

Group type: EXPERIMENTAL
Intervention: 300 mg/day modafinil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sleep restriction (5 h/night)
Number of subjects: 20
Study: 18853069

Group type: EXPERIMENTAL
Intervention: Tolyltriazole exposure during double-blind provocation test
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Metalworking fluids exposure during first provocation test
Number of subjects: 1
Study: 16279153

Group type: EXPERIMENTAL
Intervention: ISWT + PLB
Number of subjects: 69

Group type: COMPARATOR
Intervention: Baseline walk (non-PLB)
Number of subjects: 69

Group type: COMPARATOR
Intervention: ISWT (breathing normally)
Number of subjects: 69
Study: 11985939

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10100363

Group type: EXPERIMENTAL
Intervention: DDAVP spray at 20 mcg/day for 6 weeks
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: DDAVP spray at 30 mcg/day for 6 weeks
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: DDAVP spray at 20 mcg/day for 2 weeks, then 30 mcg/day for 2 weeks after washout
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: DDAVP spray at 30 mcg/day for 2 weeks, then 20 mcg/day for 2 weeks after washout
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: DDAVP spray at doses ranging from 20 to 40 mcg/day
Number of subjects: 237
Study: 8682086

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus IFN
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus thymomodulin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus IFN and thymomodulin
Number of subjects: 40
Study: 2351902

Group type: EXPERIMENTAL
Intervention: Glucolyte‐2
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional infusion
Number of subjects: 33
Study: 6158428

Group type: EXPERIMENTAL
Intervention: Relevant stimuli (diffuse and grating light flashes)
Number of subjects: 6
Study: 31973934

Group type: EXPERIMENTAL
Intervention: Coolant spray (Cryos ®Spray, Phyto Performance, Italy)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Normal saline spray (placebo)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Coolant spray
Number of subjects: 155
Study: 31221698

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (VO2peak)
Number of subjects: 150
Study: 30243419

Group type: EXPERIMENTAL
Intervention: Women's Recovery Group (WRG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group Drug Counseling (GDC)
Number of subjects: 100
Study: 26330300

Group type: EXPERIMENTAL
Intervention: Functional Restoration (FR) program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 44
Study: 24556493

Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius WB21 (2.0 × 10(9) colony‐forming units per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22465116

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive containing 20 mcg of ethinylestradiol (EE) and 3 mg of drospirenone (DRSP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: COC nonusers (control group)
Number of subjects: 71
Study: 20099364

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI (DCE-MRI) in RCC patients before surgery
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI (DCE-MRI) in antiangiogenically treated RCC patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI (DCE-MRI) in papillary RCC
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dynamic contrast-enhanced MRI (DCE-MRI) in normal kidneys
Number of subjects: 36
Study: 17963466

Group type: EXPERIMENTAL
Intervention: Combination of propofol and ketamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Propofol monotherapy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Higher doses of ketamine added to propofol
Number of subjects: 8
Study: 16131580

Group type: EXPERIMENTAL
Intervention: L-T4 (titrated to maintain low TSH)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: L-T4 (titrated to restore euthyroidism)
Number of subjects: 25
Study: 11853247

Group type: EXPERIMENTAL
Intervention: Resin-sealant (Concise) with acid etch and tooth preparation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Compomer restorative material (F2000) with acid etch, bonding agent, and tooth preparation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Compomer restorative material (F2000) with bonding agent and no tooth preparation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Compomer restorative material (F2000) with bonding agent and tooth preparation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Compomer restorative material (F2000) with bonding agent and without enameloplasty
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sealant with acid etching and enameloplasty
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Compomer with acid etching and bonding agent
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enameloplasty and acid etching
Number of subjects: 30
Study: 10885910

Group type: EXPERIMENTAL
Intervention: irinotecan
Number of subjects: 256

Group type: COMPARATOR
Intervention: infusional 5-FU
Number of subjects: 256
Study: 8950882

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg per day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 15
Study: 1827053

Group type: EXPERIMENTAL
Intervention: Butorphanol 20 micrograms.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl 1 microgram.kg‐1
Number of subjects: 60
Study: 7039533

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (30 to 60 mg orally for six days before operation)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no coenzyme Q10)
Number of subjects: 50
Study: 31763265

Group type: EXPERIMENTAL
Intervention: Endoscopic turbinoplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional partial inferior turbinectomy
Number of subjects: 60
Study: 28835059

Group type: EXPERIMENTAL
Intervention: Group A (hydromorphone hydrochloride 1 μg·kg(‐1)·h(‐1) + flurbiprofen axetil 200 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group B (hydromorphone hydrochloride 2 μg·kg(‐1)·h(‐1))
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group C (hydromorphone hydrochloride 1 μg·kg(‐1)·h(‐1))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group C
Number of subjects: 100
Study: 25676147

Group type: EXPERIMENTAL
Intervention: Solitaire stent retriever (roll-in period)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solitaire stent retriever (randomized phase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Solitaire stent retriever
Number of subjects: 0
Study: 24770960

Group type: EXPERIMENTAL
Intervention: Alcohol SPN (1 ml of absolute alcohol injected under CT guidance)
Number of subjects: 42
Study: 22497427

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 158

Group type: COMPARATOR
Intervention: Famotidine 40 mg/day
Number of subjects: 158
Study: 19841919

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 6

Group type: COMPARATOR
Intervention: Unreamed intramedullary nailing
Number of subjects: 6
Study: 18020851

Group type: EXPERIMENTAL
Intervention: Willingness to use microbicides
Number of subjects: 531
Study: 16168806

Group type: EXPERIMENTAL
Intervention: Percutaneous myocardial laser (PML)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 82
Study: 12072587

Group type: EXPERIMENTAL
Intervention: Salmeterol 84 microg every 12 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 8
Study: 10416552

Group type: EXPERIMENTAL
Intervention: High-intensity residential exercise training program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 7587855

Group type: COMPARATOR
Intervention: AC137 infusion (50 micrograms/h) during a standardized Sustacal meal (350 kcal) challenge.
Number of subjects: 24

Group type: COMPARATOR
Intervention: AC137 infusion (steady-state concentrations of 234 +/- 16 pmol/l) during an intravenous glucose load (300 mg/kg).
Number of subjects: 24
Study: 2210097

Group type: EXPERIMENTAL
Intervention: 80 mM glucose-sodium chloride solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose concentrations greater than 250 mM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ileal glucose-stimulated water absorption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jejunal glucose absorption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ileal glucose absorption
Number of subjects: 0
Study: 6951257

Group type: EXPERIMENTAL
Intervention: Biofeedback training (up to six times, 30 min per session)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Full coverage splints at night for 6 weeks
Number of subjects: 30
Study: 31568868

Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve interventions (TTVI)
Number of subjects: 1651
Study: 29276868

Group type: EXPERIMENTAL
Intervention: Nebulized adrenaline mixed with 3% hypertonic saline
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Nebulized adrenaline
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 378

Group type: COMPARATOR
Intervention: Normal saline (0.9% NaCl)
Number of subjects: 378
Study: 26547414

Group type: EXPERIMENTAL
Intervention: LF-0.6 (formula with 0.6 g/L bLf)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: LF-1.0 (formula with 1.0 g/L bLf)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control (cow's milk-based formula)
Number of subjects: 480
Study: 23340303

Group type: EXPERIMENTAL
Intervention: Paclitaxel with bevacizumab
Number of subjects: 363

Group type: COMPARATOR
Intervention: Paclitaxel without bevacizumab (control)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Paclitaxel with or without bevacizumab
Number of subjects: 363
Study: 21795437

Group type: EXPERIMENTAL
Intervention: Intentional weight loss intervention
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Weight regain (≥2 kg)
Number of subjects: 78